11314

    211608

    BALAXI

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    BALAXI PHARMA LTD Share Price Today

    BALAXI PHARMA LTD is currently trading at ₹24.38, up by ₹0.2 from the previous close. The stock touched an intraday high of ₹24.50 and a low of ₹23.61 during the latest trading session. Over the past one year, BALAXI PHARMA LTD has delivered a loss of 51.52%, while the stock has declined 0.57% in the last one month.

    BALAXI PHARMA LTD performance

    Today’s low Today’s high
    ₹ 23.61 ₹ 24.50
    ₹ 24.30
    52 week low 52 week high
    ₹ 15.20 ₹ 52.50
    ₹ 24.30
    Open Price ₹ 24.45
    Prev. Close ₹ 24.17
    Volume (Shares) 11041.00
    Total traded value ₹ 2.68
    Upper Circuit ₹ 25.37
    Lower Circuit ₹ 22.97
    info

    Investment Returns

    Over 1 Month -0.57% Over 3 Months 1.59% Over 6 Months -3.74% Over 1 Year -51.52%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    BALAXI PHARMA LTD fundamentals


    • Market cap (Cr) 134.20
    • P/E Ratio (TTM) 25.99
    • Beta 1.05
    • Book Value / share 24.09
    • Return on equity 2.89%
    • EPS (TTM) 0.93
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 0.16
    info icon alternate text
    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) [-]
    info icon alternate text

    BALAXI PHARMA LTD Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 20.24
    Operating Expense 23.19
    Net Profit 0.16
    Net Profit Margin (%) 0.79
    Earnings Per Share (EPS) 0.03
    EBITDA 1.43
    Effective Tax Rate (%) 63.41
    Particulars DEC 2025 (Values in Cr)
    Revenue 24.59
    Operating Expense 24.09
    Net Profit 1.53
    Net Profit Margin (%) 6.22
    Earnings Per Share (EPS) 0.28
    EBITDA 3.00
    Effective Tax Rate (%) 27.83
    Particulars SEP 2025 (Values in Cr)
    Revenue 19.31
    Operating Expense 19.28
    Net Profit 3.26
    Net Profit Margin (%) 16.88
    Earnings Per Share (EPS) 0.59
    EBITDA 4.98
    Effective Tax Rate (%) 23.11
    Particulars JUN 2025 (Values in Cr)
    Revenue 16.71
    Operating Expense 16.91
    Net Profit 0.19
    Net Profit Margin (%) 1.13
    Earnings Per Share (EPS) 0.04
    EBITDA 1.00
    Effective Tax Rate (%) 23.07
    Particulars MAR 2025 (Values in Cr)
    Revenue 9.65
    Operating Expense 11.10
    Net Profit -1.18
    Net Profit Margin (%) -12.22
    Earnings Per Share (EPS) -0.21
    EBITDA -0.33
    Effective Tax Rate (%) -3.50
    Particulars MAR 2026 (Values in Cr)
    Revenue 80.85
    Operating Expense 83.49
    Net Profit 5.15
    Net Profit Margin (%) 6.36
    Earnings Per Share (EPS) 0.93
    EBITDA 10.43
    Effective Tax Rate (%) 26.88
    Particulars MAR 2025 (Values in Cr)
    Revenue 60.99
    Operating Expense 61.08
    Net Profit 3.60
    Net Profit Margin (%) 5.90
    Earnings Per Share (EPS) 0.65
    EBITDA 7.81
    Effective Tax Rate (%) 31.94
    Particulars MAR 2024 (Values in Cr)
    Revenue 70.20
    Operating Expense 67.01
    Net Profit 3.65
    Net Profit Margin (%) 5.19
    Earnings Per Share (EPS) 3.55
    EBITDA 7.63
    Effective Tax Rate (%) 34.58
    Particulars MAR 2023 (Values in Cr)
    Revenue 108.14
    Operating Expense 92.28
    Net Profit 16.22
    Net Profit Margin (%) 14.99
    Earnings Per Share (EPS) 16.17
    EBITDA 23.43
    Effective Tax Rate (%) 27.75
    Particulars MAR 2022 (Values in Cr)
    Revenue 101.29
    Operating Expense 84.34
    Net Profit 14.67
    Net Profit Margin (%) 14.48
    Earnings Per Share (EPS) 14.67
    EBITDA 20.00
    Effective Tax Rate (%) 25.53
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 41.98
    ROE % 11.58
    ROCE % 12.91
    Total Debt to Total Equity 0.17
    EBITDA Margin 11.82
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 36.26
    ROE % -25.94
    ROCE % 20.69
    Total Debt to Total Equity 0.09
    EBITDA Margin 18.75
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 169.51
    ROE % 31.05
    ROCE % 37.25
    Total Debt to Total Equity 0.06
    EBITDA Margin 17.85
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 113.16
    ROE % 53.51
    ROCE % 59.62
    Total Debt to Total Equity 0.04
    EBITDA Margin 19.97
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 64.98
    ROE % 82.26
    ROCE % 92.56
    Total Debt to Total Equity 0.04
    EBITDA Margin 19.41
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 23.16
    ROE % 2.89
    ROCE % 5.06
    Total Debt to Total Equity 0.19
    EBITDA Margin 13.08
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 21.61
    ROE % 3.42
    ROCE % 5.99
    Total Debt to Total Equity 0.13
    EBITDA Margin 11.04
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 80.35
    ROE % 21.62
    ROCE % 27.93
    Total Debt to Total Equity 0.10
    EBITDA Margin 21.71
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 57.91
    ROE % 29.00
    ROCE % 37.15
    Total Debt to Total Equity 0.05
    EBITDA Margin 19.79
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 43.25
    ROE % 42.40
    ROCE % 55.40
    Total Debt to Total Equity 0.05
    EBITDA Margin 23.98
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 39.39
    Total Assets 310.34
    Total Liabilities 310.34
    Total Equity 231.73
    Share Outstanding 5
    Price to Book Ratio 2.76
    Return on Assets (%) 8.07
    Return on Capital (%) 8.85
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 62.29
    Total Assets 258.34
    Total Liabilities 258.34
    Total Equity 201.36
    Share Outstanding 5
    Price to Book Ratio 22.95
    Return on Assets (%) -0.92
    Return on Capital (%) -1.09
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 28.21
    Total Assets 239.66
    Total Liabilities 239.66
    Total Equity 182.87
    Share Outstanding 1
    Price to Book Ratio 6.60
    Return on Assets (%) 19.17
    Return on Capital (%) 23.63
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 7.19
    Total Assets 176.47
    Total Liabilities 176.47
    Total Equity 113.16
    Share Outstanding 1
    Price to Book Ratio 6.07
    Return on Assets (%) 27.00
    Return on Capital (%) 40.8
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 1.66
    Total Assets 99.67
    Total Liabilities 99.67
    Total Equity 64.97
    Share Outstanding 1
    Price to Book Ratio 12.13
    Return on Assets (%) 38.25
    Return on Capital (%) 55.56
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 28.68
    Total Assets 174.44
    Total Liabilities 174.44
    Total Equity 127.85
    Share Outstanding 5
    Price to Book Ratio 2.76
    Return on Assets (%) 2.06
    Return on Capital (%) 2.28
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 44.06
    Total Assets 154.36
    Total Liabilities 154.36
    Total Equity 121.54
    Share Outstanding 5
    Price to Book Ratio 22.95
    Return on Assets (%) 2.36
    Return on Capital (%) 2.69
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 17.87
    Total Assets 129.72
    Total Liabilities 129.72
    Total Equity 92.10
    Share Outstanding 1
    Price to Book Ratio 6.60
    Return on Assets (%) 12.50
    Return on Capital (%) 15.77
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.84
    Total Assets 81.91
    Total Liabilities 81.91
    Total Equity 57.91
    Share Outstanding 1
    Price to Book Ratio 6.07
    Return on Assets (%) 17.90
    Return on Capital (%) 24.51
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 0.47
    Total Assets 68.91
    Total Liabilities 68.91
    Total Equity 43.24
    Share Outstanding 1
    Price to Book Ratio 12.13
    Return on Assets (%) 21.95
    Return on Capital (%) 32.37
    Particulars MAR 2025 (Values in Cr)
    Net Income 28.66
    Cash from Operations -31.79
    Cash from Investing -21.76
    Cash from Financing 33.87
    Net change in Cash -22.89
    Free Cash Flow -30.43
    Particulars MAR 2024 (Values in Cr)
    Net Income 2.01
    Cash from Operations 11.54
    Cash from Investing -1.04
    Cash from Financing 30.25
    Net change in Cash 34.07
    Free Cash Flow 12.23
    Particulars MAR 2023 (Values in Cr)
    Net Income 56.92
    Cash from Operations 18.16
    Cash from Investing -10.56
    Cash from Financing 25.51
    Net change in Cash 21.02
    Free Cash Flow 31.22
    Particulars MAR 2022 (Values in Cr)
    Net Income 54.52
    Cash from Operations 39.73
    Cash from Investing -28.44
    Cash from Financing -0.16
    Net change in Cash 5.53
    Free Cash Flow 44.48
    Particulars MAR 2021 (Values in Cr)
    Net Income 44.32
    Cash from Operations 2.59
    Cash from Investing -5.97
    Cash from Financing 3.64
    Net change in Cash -2.32
    Free Cash Flow 3.87
    Particulars MAR 2025 (Values in Cr)
    Net Income 5.28
    Cash from Operations -5.96
    Cash from Investing -24.98
    Cash from Financing 17.21
    Net change in Cash -15.37
    Free Cash Flow -5.93
    Particulars MAR 2024 (Values in Cr)
    Net Income 5.58
    Cash from Operations 3.24
    Cash from Investing 0.46
    Cash from Financing 27.55
    Net change in Cash 26.18
    Free Cash Flow 3.27
    Particulars MAR 2023 (Values in Cr)
    Net Income 22.45
    Cash from Operations -1.65
    Cash from Investing -2.29
    Cash from Financing 26.39
    Net change in Cash 17.03
    Free Cash Flow 0.71
    Particulars MAR 2022 (Values in Cr)
    Net Income 19.69
    Cash from Operations 14.57
    Cash from Investing -6.87
    Cash from Financing -1.63
    Net change in Cash 0.37
    Free Cash Flow 16.33
    Particulars MAR 2021 (Values in Cr)
    Net Income 20.59
    Cash from Operations 15.89
    Cash from Investing -20.03
    Cash from Financing 3.49
    Net change in Cash -3.08
    Free Cash Flow 16.49
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.82 12.79 1.49 236.18 23.12 38.85
    BLISS GVS PHARMA LTD. 521.10 41.89 4.63 5526.59 118.35 552.90
    CIPLA LTD 1438.75 30.53 3.37 116228.74 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 411.65 18.16 2.97 1211.53 256.40 415.70
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.82 21.55 3.97 236.18 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 540.85 24.24 4.22 1563.63 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8123.85 106.10 23.26 20309.63 7630.00 9850.00
    BLISS GVS PHARMA LTD. 521.10 56.34 4.78 5526.59 118.35 552.90

    BALAXI PHARMA LTD shareholding pattern

    Holding
    31.44%
    65.99%
    2.56%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    BALAXI PHARMA LTD Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    24.30 0.53 redarrow
    red-green-graph indicator
    4 Bearish
    12 Bullish
    • 5 Days 24.00
    • 26 Days 24.00
    • 10 Days 23.90
    • 50 Days 24.20
    • 12 Days 23.90
    • 100 Days 25.10
    • 20 Days 23.90
    • 200 Days 30.90
    24.15 PIVOT
    First Support 24.02 First Resistance 24.29 Second Support 23.88 Second Resistance 24.42 Third Support 23.75 Third Resistance 24.56
    RSI 51.97 ADX 37.05 MACD -0.23 Williams % R -31.84 Commodity Channel Index (CCI) 116.09
    Date 2026-04-20 Week 60302.00 Same Day 33075.00 Month 170631.00
    1 Year 1.06 3 Year 0.96
    Over 1 Month
    -0.57% down
    Over 1 Year
    -51.52% down
    Over 3 Months
    1.59% down
    Over 3 Years
    -38.48% down
    Over 6 Months
    -3.74% down
    Over 5 Years
    -27.43% down

    BALAXI PHARMA LTD Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    01 Jul 2022 0.5 Final 04 Jul 2022 Equity shares
    Ex-Date Old FV NEW FV Record Date
    30 May 2024 10.0 2.0 30 May 2024
    Dividend date Dividend amount Dividend type Record date Instrument type
    01 Jul 2022 0.5 Final 04 Jul 2022 Equity shares
    Ex-Date Old FV NEW FV Record Date
    30 May 2024 10.0 2.0 30 May 2024

    Top Gainers

    Top Losers

    Balaxi Pharma Ltd Share Highlights

    Balaxi Pharmaceuticals has shown a mixed performance for the quarter ending June 2024. Despite a slight decline in net sales, which dipped by 0.51% year-over-year to Rs 65.62 crore, the company achieved a significant increase in net profit. The net profit soared by 115.67%, reaching Rs 6.48 crore compared to Rs 3.01 crore in the same period last year. Read More... The EBITDA also saw a modest rise of 5.1%, standing at Rs 8.24 crore. This strong profitability, despite flat sales, may positively influence the Balaxi Pharma share price. Investors are likely to view this as a sign of improved operational efficiency and profitability, which could drive future growth. Read Less

    Balaxi Pharma Ltd Share Annual Reports

    The annual report of Balaxi Pharmaceuticals offers a detailed overview of the company's financial and operational performance over the past fiscal year. It provides insights into revenue streams, cost management, and profitability, which are crucial for understanding the company's overall health and growth prospects. For those tracking the Balaxi Pharma share price, Read More...the annual report is an essential document that sheds light on the company's strategic direction, market positioning, and potential for future growth. It also includes information on the company’s governance practices and sustainability initiatives, providing a comprehensive picture of its operations.  Read Less

    Balaxi Pharma Ltd Share Dividend

    Balaxi Pharmaceuticals' dividend policy is a key point of interest for investors, particularly given the company's strong net profit growth in the recent quarter. While net sales remained relatively flat, the significant increase in profitability could result in favorable dividend payouts. The Balaxi Pharma share price could be positively impacted by a strong dividend announcement, signaling the company’s commitment to returning value to its shareholders. Investors will be looking closely at the upcoming dividend declaration to gauge the company’s financial stability and its approach to balancing growth with shareholder returns.

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Balaxi Pharmaceuticals Ltd?

    Answer Field

    Balaxi Pharmaceuticals Ltd share price is for NSE ₹ 24.38 & for BSE ₹ 0.00 as on Jul 13 2026 03:27 PM.

    What is the Market Cap of Balaxi Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Balaxi Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 13 2026 03:27 PM.

    What is the 52 Week High and Low of Balaxi Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Balaxi Pharmaceuticals Ltd for NSE is ₹ 52.50 and ₹ 15.20 and for BSE is ₹ 0.00 and ₹ 0.00.

    What is 1 year return for Balaxi Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been -51.52%.

    What is the P/E Ratio of Balaxi Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 13 2026 03:27 PM the price-to-earnings (PE) ratio for Balaxi Pharmaceuticals Ltd share is 25.99.

    What is the PB ratio of Balaxi Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 13 2026 03:27 PM, the price-to-book (PB) ratio for Balaxi Pharmaceuticals Ltd share is 24.09.

    How to Buy Balaxi Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Balaxi Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Balaxi Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Balaxi Pharmaceuticals Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    What is the Balaxi Pharmaceuticals Share price?

    Answer Field

    The share price of Balaxi Pharmaceuticals Ltd for NSE is ₹ 110.81 and for BSE is ₹ 0.00.

    What is the Market Cap of Balaxi Pharmaceuticals Ltd?

    Answer Field

    The market cap of Balaxi Pharmaceuticals Ltd for NSE is ₹ 1,20.75 Cr. and for BSE is ₹ 0.0 Cr. as of now.

    What is the 52W high & 52W low of Balaxi Pharmaceuticals Share?

    Answer Field

    The 52 Week High and Low of Balaxi Pharmaceuticals Ltd for NSE is ₹ 151.45 and ₹ 79.99 and for BSE is ₹ 0.00 and ₹ 0.00.

    How to buy Balaxi Pharmaceuticals Share?

    Answer Field

    You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

    What is one year return for Balaxi Pharmaceuticals Share?

    Answer Field

    The 1 year returns on the stock has been 16.86%.

    What is the P/E ratio of Balaxi Pharma Share in 2024?

    Answer Field

    As of August 17, 2024, Balaxi Pharmaceuticals' P/E ratio was 13.4. This is a 61% discount to the median range of 34.67 times for its peers.

    What is the PB ratio of Balaxi Pharma Share in 2024?

    Answer Field

    As of August 17, 2024, Balaxi Pharmaceuticals Ltd.'s price-to-book (PB) ratio was 3. This is considered a low PB ratio.

    Who is the CEO of Balaxi Pharma Limited?

    Answer Field

    Ashish Maheshwari is the Chairman and Managing Director of Balaxi Pharmaceuticals Limited. He is also the founder of Balaxi Pharmaceuticals and the Balaxi Group.

    When was Balaxi Pharma established?

    Answer Field

    Balaxi Pharma was established in 1942.

    How to buy Balaxi Pharma Share on Bajaj Broking App?

    Answer Field

    To buy Balaxi Pharma shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Balaxi Pharma”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase.

    Is Balaxi Pharma debt free?

    Answer Field

    As of August 15, 2024, Balaxi Pharmaceuticals Ltd. (NSE: BALAXI) has negative net debt, meaning it has more cash and short-term investments than debt. Balaxi's debt to equity (D/E) ratio is 0.1, and it has short-term assets that exceed short-term liabilities. Balaxi also has a high Altman Z-score of 4.21, and its long-term assets exceed long-term liabilities. 

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |